Anticancer Drug Combinations, A Big Momentum is Needed

Lu DY Chen EH, Ding J Xu B
2015 Journal of Postgenomics Drug & Biomarker Development  
to cytotoxic anticancer drugs often occurs in regrowed cancer cells. Yet cytotoxic anticancer drugs are good partner with most other types of anticancer (targeted agents), biotherapy or assistant therapies. Introductions of general ideas and different drug combination modular Previously, combination utilizations of cytotoxic anticancer chemicals with biotherapy or other therapeutic means are good strategies for cancer treatments [8] [9] [10] . Many similar examples are given later and will be
more » ... scussed one by one. Several modular of anticancer drug combination systems are temporarily categorized as followings; Abstract Most cancer therapies are seldom effective by using one anticancer drug owing to refractory and resistance property of cancer tissues caused by multiple genetic alterations and molecular abnormalities. Despite great popularity of anticancer drug combination utilizations, the hidden rules behind scenarios emerge in new era of anticancer therapy. Most importantly, anticancer drug cocktails need to transform from empirical to science-guided enterprises. This editorial offers the background knowledge of drug combination therapy across the history. Possible future landscapes and drawbacks of current cancer drug combinative therapy are addressed and speculated. Me ta b o lo m ics: O p e n A c ce ss
doi:10.4172/2153-0769.1000e139 fatcat:re6j4docpjfq3nzppi3cpgv324